Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Symposium 4: Sex hormone abnormalities

Obesity, insulin, sex steroids and ovulation


Obesity is a major feature in women with polycystic ovary syndrome (PCOS), and evidence suggests that obesity contributes to the pathogenesis of PCOS by aggravating the intrinsic insulin resistance of these women. Hyperinsulinemia appears to increase circulating androgens in PCOS by stimulating ovarian androgen production and suppressing serum SHBG, and also appears to play a pathogenic role in the anovulation of the disorder. The use of insulin sensitizing drugs has been shown to decrease serum insulin in both obese and nonobese women with PCOS, and to simultaneously reduce circulating ovarian androgens and to improve ovulation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations


Corresponding author

Correspondence to JE Nestler.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nestler, J. Obesity, insulin, sex steroids and ovulation. Int J Obes 24 (Suppl 2), S71–S73 (2000).

Download citation

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links